A side-by-side comparison of two Healthcare investors: Catalio Capital Management (Power Score 82/100) and Deerfield Management (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Catalio Capital Management | Deerfield Management | |
|---|---|---|
| Power Score™ | 82/100 | 83/100 |
| Assets Managed | $2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) | More than $16B (in assets as of December 2025, per the firm's own About page; the figure could not be checked against Form ADV Item 5.F) |
| Founded | 2020 | 1994 |
| Headquarters | New York, NY | New York, NY |
| Sectors | Healthcare, Biotech, Medical Devices, Diagnostics, Life Sciences, Data | Therapeutics, Medical Devices, Healthcare, Diagnostics, Digital Health, Life Sciences |
Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.
View full Catalio Capital Management profile →Deerfield describes itself as an investment firm dedicated to advancing healthcare through investment, intelligence and philanthropy, and says it holds a portfolio of more than two hundred private and public investments spanning therapeutics, medical devices, healthcare services, diagnostics and digital health. It states that it invests across capital structures and across company stages, from early-stage startups to mature companies, and that it offers structured finance solutions and customised financing for entrepreneurs and corporate partners in both public and private markets. Alongside the funds it runs an in-house research and data organisation: Deerfield Intelligence is described as the firm's data, technology and AI arm, and Deerfield Discovery and Development (3DC) as its internal R&D engine, taking early-stage therapeutics from discovery through preclinical proof of concept into clinical development. Deerfield also builds companies with academic and health-system partners through named discovery alliances. It is an SEC-registered investment adviser (CRD 157876, SEC file 801-73284) and files quarterly 13F reports covering listed equities, ADSs and convertible notes, so its public-market activity sits alongside its private investing rather than replacing it.
View full Deerfield Management profile →